Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study.
Megna M, Di Costanzo L, Argenziano G, Balato A, Colasanti P, Cusano F, Galluccio AG, Gambardella A, Lembo S, Mozzillo R, Scotto Di Luzio G, Fabbrocini G, Balato N. Megna M, et al. Among authors: galluccio ag. Expert Opin Biol Ther. 2019 Aug;19(8):855-861. doi: 10.1080/14712598.2019.1622678. Epub 2019 May 29. Expert Opin Biol Ther. 2019. PMID: 31140882
Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data.
Cassano N, Galluccio A, De Simone C, Loconsole F, Massimino SD, Plumari A, Dattola S, Puglisi Guerra A, Donato L, Cantoresi F, De Pita O, Fenizi G, Altamura V, Congedo M, Pellicano R, Vena GA. Cassano N, et al. J Biol Regul Homeost Agents. 2008 Oct-Dec;22(4):233-7. J Biol Regul Homeost Agents. 2008. PMID: 19036225 Clinical Trial.
A multicenter open-label experience on the response of psoriasis to Adalimumab and effect of dose escalation in non-responders: the Aphrodite project.
Vena GA, Galluccio A, De Simone C, Mastrandrea V, Buquicchio R, La Greca S, Dattola S, Puglisi Guerra A, Donato L, Cantoresi F, De Pità O, Pezza M, D Agostino M, Vernaci R, Miracapillo A, Valenti G, Cassano N. Vena GA, et al. Int J Immunopathol Pharmacol. 2009 Jan-Mar;22(1):227-33. doi: 10.1177/039463200902200125. Int J Immunopathol Pharmacol. 2009. PMID: 19309570 Free article.
Treatment of psoriasis with different dosage regimens of etanercept: preliminary results from the Tαranta Plastic Study Group.
Cassano N, Loconsole F, Miracapillo A, Travaglini M, Digiuseppe MD, Congedo M, Galluccio A, Buquicchio R, Mastrandrea V, Filieri M, Raho G, Pezza M, Vena GA. Cassano N, et al. Int J Immunopathol Pharmacol. 2010 Jul-Sep;23(3):797-802. doi: 10.1177/039463201002300314. Int J Immunopathol Pharmacol. 2010. PMID: 20943050 Free article. Clinical Trial.
Treating psoriasis with etanercept in italian clinical practice: prescribing practices and duration of remission following discontinuation.
Arcese A, Aste N, Bettacchi A, Camplone G, Cantoresi F, Caproni M, D'Amico D, Fabbri P, Filosa G, Galluccio A, Hansel K, Lisi P, Micali G, Musumeci ML, Nicolini M, Parodi A, Patania M, Pezza M, Potenza C, Richetta A, Simonacci M, Trevisan P, Valenti G, Calvieri S. Arcese A, et al. Clin Drug Investig. 2010;30(8):507-16. doi: 10.2165/11537470-000000000-00000. Clin Drug Investig. 2010. PMID: 20586516
The safety of anti-TNF agents in the elderly.
Migliore A, Bizzi E, Laganà B, Altomonte L, Zaccari G, Granata M, Canzoni M, Marasini B, Massarotti M, Massafra U, Ranieri M, Pilla R, Martin LS, Pezza M, Vacca F, Galluccio A. Migliore A, et al. Int J Immunopathol Pharmacol. 2009 Apr-Jun;22(2):415-26. doi: 10.1177/039463200902200218. Int J Immunopathol Pharmacol. 2009. PMID: 19505394 Free article.
18 results